Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy

Elias Jabbour, Guillermo Garcia-Manero, Nicolas Batty, Jenny Shan, Susan O'Brien, Jorge Cortes, Farhad Ravandi, Jean Pierre Issa, Hagop Kantarjian

Research output: Contribution to journalArticle

Abstract

BACKGROUND: The prognosis of patients with myelodysplastic syndrome (MDS) after decitabine failure is not known. METHODS: Data from 87 patients with MDS (n = 67) and chronic myelomonocytic leukemia (n = .20) after failure of decitabine regimens were reviewed. RESULTS: After a median follow-up of 21 months from decitabine failure, 13 (15%) patients remained alive; the median survival was 4.3 months, and the estimated 12-month survival rate was 28%. The estimated 12-month survival rates were 27%, 33%, and 33%, respectively, for patients with high-risk, intermediate-2-risk, and intermediate-1-risk disease (P = .99) by the International Prognostic Scoring System. The estimated 12-month survival rates were 100%, 54%, 41%, and 18%, respectively, for patients with low-risk, intermediate-1-risk, intermediate-2-risk, and high-risk disease according to The University of Texas M. D. Anderson Cancer Center risk model (P = .01). CONCLUSIONS: The outcome of patients after decitabine failure is poor and appears to be predictable after decitabine failure.

Original languageEnglish (US)
Pages (from-to)3830-3834
Number of pages5
JournalCancer
Volume116
Issue number16
DOIs
StatePublished - Aug 15 2010
Externally publishedYes

Fingerprint

decitabine
Myelodysplastic Syndromes
Survival Rate
Therapeutics
Leukemia, Myelomonocytic, Chronic

Keywords

  • Decitabine
  • Failure
  • Myelodysplastic syndrome
  • Prognosis

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Jabbour, E., Garcia-Manero, G., Batty, N., Shan, J., O'Brien, S., Cortes, J., ... Kantarjian, H. (2010). Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy. Cancer, 116(16), 3830-3834. https://doi.org/10.1002/cncr.25247

Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy. / Jabbour, Elias; Garcia-Manero, Guillermo; Batty, Nicolas; Shan, Jenny; O'Brien, Susan; Cortes, Jorge; Ravandi, Farhad; Issa, Jean Pierre; Kantarjian, Hagop.

In: Cancer, Vol. 116, No. 16, 15.08.2010, p. 3830-3834.

Research output: Contribution to journalArticle

Jabbour, E, Garcia-Manero, G, Batty, N, Shan, J, O'Brien, S, Cortes, J, Ravandi, F, Issa, JP & Kantarjian, H 2010, 'Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy', Cancer, vol. 116, no. 16, pp. 3830-3834. https://doi.org/10.1002/cncr.25247
Jabbour E, Garcia-Manero G, Batty N, Shan J, O'Brien S, Cortes J et al. Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy. Cancer. 2010 Aug 15;116(16):3830-3834. https://doi.org/10.1002/cncr.25247
Jabbour, Elias ; Garcia-Manero, Guillermo ; Batty, Nicolas ; Shan, Jenny ; O'Brien, Susan ; Cortes, Jorge ; Ravandi, Farhad ; Issa, Jean Pierre ; Kantarjian, Hagop. / Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy. In: Cancer. 2010 ; Vol. 116, No. 16. pp. 3830-3834.
@article{662b416ce0154e9a914fb64e0b1dbb1c,
title = "Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy",
abstract = "BACKGROUND: The prognosis of patients with myelodysplastic syndrome (MDS) after decitabine failure is not known. METHODS: Data from 87 patients with MDS (n = 67) and chronic myelomonocytic leukemia (n = .20) after failure of decitabine regimens were reviewed. RESULTS: After a median follow-up of 21 months from decitabine failure, 13 (15{\%}) patients remained alive; the median survival was 4.3 months, and the estimated 12-month survival rate was 28{\%}. The estimated 12-month survival rates were 27{\%}, 33{\%}, and 33{\%}, respectively, for patients with high-risk, intermediate-2-risk, and intermediate-1-risk disease (P = .99) by the International Prognostic Scoring System. The estimated 12-month survival rates were 100{\%}, 54{\%}, 41{\%}, and 18{\%}, respectively, for patients with low-risk, intermediate-1-risk, intermediate-2-risk, and high-risk disease according to The University of Texas M. D. Anderson Cancer Center risk model (P = .01). CONCLUSIONS: The outcome of patients after decitabine failure is poor and appears to be predictable after decitabine failure.",
keywords = "Decitabine, Failure, Myelodysplastic syndrome, Prognosis",
author = "Elias Jabbour and Guillermo Garcia-Manero and Nicolas Batty and Jenny Shan and Susan O'Brien and Jorge Cortes and Farhad Ravandi and Issa, {Jean Pierre} and Hagop Kantarjian",
year = "2010",
month = "8",
day = "15",
doi = "10.1002/cncr.25247",
language = "English (US)",
volume = "116",
pages = "3830--3834",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "16",

}

TY - JOUR

T1 - Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy

AU - Jabbour, Elias

AU - Garcia-Manero, Guillermo

AU - Batty, Nicolas

AU - Shan, Jenny

AU - O'Brien, Susan

AU - Cortes, Jorge

AU - Ravandi, Farhad

AU - Issa, Jean Pierre

AU - Kantarjian, Hagop

PY - 2010/8/15

Y1 - 2010/8/15

N2 - BACKGROUND: The prognosis of patients with myelodysplastic syndrome (MDS) after decitabine failure is not known. METHODS: Data from 87 patients with MDS (n = 67) and chronic myelomonocytic leukemia (n = .20) after failure of decitabine regimens were reviewed. RESULTS: After a median follow-up of 21 months from decitabine failure, 13 (15%) patients remained alive; the median survival was 4.3 months, and the estimated 12-month survival rate was 28%. The estimated 12-month survival rates were 27%, 33%, and 33%, respectively, for patients with high-risk, intermediate-2-risk, and intermediate-1-risk disease (P = .99) by the International Prognostic Scoring System. The estimated 12-month survival rates were 100%, 54%, 41%, and 18%, respectively, for patients with low-risk, intermediate-1-risk, intermediate-2-risk, and high-risk disease according to The University of Texas M. D. Anderson Cancer Center risk model (P = .01). CONCLUSIONS: The outcome of patients after decitabine failure is poor and appears to be predictable after decitabine failure.

AB - BACKGROUND: The prognosis of patients with myelodysplastic syndrome (MDS) after decitabine failure is not known. METHODS: Data from 87 patients with MDS (n = 67) and chronic myelomonocytic leukemia (n = .20) after failure of decitabine regimens were reviewed. RESULTS: After a median follow-up of 21 months from decitabine failure, 13 (15%) patients remained alive; the median survival was 4.3 months, and the estimated 12-month survival rate was 28%. The estimated 12-month survival rates were 27%, 33%, and 33%, respectively, for patients with high-risk, intermediate-2-risk, and intermediate-1-risk disease (P = .99) by the International Prognostic Scoring System. The estimated 12-month survival rates were 100%, 54%, 41%, and 18%, respectively, for patients with low-risk, intermediate-1-risk, intermediate-2-risk, and high-risk disease according to The University of Texas M. D. Anderson Cancer Center risk model (P = .01). CONCLUSIONS: The outcome of patients after decitabine failure is poor and appears to be predictable after decitabine failure.

KW - Decitabine

KW - Failure

KW - Myelodysplastic syndrome

KW - Prognosis

UR - http://www.scopus.com/inward/record.url?scp=77956862198&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956862198&partnerID=8YFLogxK

U2 - 10.1002/cncr.25247

DO - 10.1002/cncr.25247

M3 - Article

C2 - 20564137

AN - SCOPUS:77956862198

VL - 116

SP - 3830

EP - 3834

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 16

ER -